{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T01:25:43Z","timestamp":1789262743744,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007805","name":"Fondation du Coll\u00e8ge de France","doi-asserted-by":"publisher","award":["QGC606"],"award-info":[{"award-number":["QGC606"]}],"id":[{"id":"10.13039\/501100007805","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-14-LAB6-0001"],"award-info":[{"award-number":["ANR-14-LAB6-0001"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["PBR201810007643"],"award-info":[{"award-number":["PBR201810007643"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.cjca.2022.01.019","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T22:06:22Z","timestamp":1643148382000},"page":"815-827","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["QGC606: A Best-in-Class Orally Active Centrally Acting Aminopeptidase A Inhibitor Prodrug for Treating Heart Failure Following Myocardial Infarction"],"prefix":"10.1016","volume":"38","author":[{"given":"Sol\u00e8ne E.","family":"Boitard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Keck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Deloux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Emmanuel","family":"Girault-Sotias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Marc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"De Mota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Compere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onnik","family":"Agbulut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Balavoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7667-0401","authenticated-orcid":false,"given":"Catherine","family":"Llorens-Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2022.01.019_bib1","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","volume":"342","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2022.01.019_bib2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1517\/14656566.6.3.507","article-title":"VALIANT (VALsartan In Acute myocardial iNfarcTion) trial","volume":"6","author":"Maggioni","year":"2005","journal-title":"Exp Opin Pharmacother"},{"key":"10.1016\/j.cjca.2022.01.019_bib3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Investigators SOLVD. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2022.01.019_bib4","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/00005344-200010000-00009","article-title":"Effects of ACE inhibitor, AT1 antagonist, and combined treatment in mice with heart failure","volume":"36","author":"Cavasin","year":"2000","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.cjca.2022.01.019_bib5","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1161\/circ.104.17.2118","article-title":"ACC\/AHA\/ESC guidelines for the management of patients with atrial fibrillation","volume":"104","author":"Fuster","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2022.01.019_bib6","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1161\/01.CIR.95.12.2643","article-title":"Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction: the healing and early afterload reducing therapy trial","volume":"95","author":"Pfeffer","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2022.01.019_bib7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1161\/CIRCRESAHA.107.158261","article-title":"Brain mechanisms contributing to sympathetic hyperactivity and heart failure","volume":"101","author":"Leenen","year":"2007","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2022.01.019_bib8","doi-asserted-by":"crossref","first-page":"11968","DOI":"10.1073\/pnas.93.21.11968","article-title":"Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release","volume":"93","author":"Zini","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cjca.2022.01.019_bib9","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1021\/jm00044a016","article-title":"Differential inhibition of aminopeptidase A and aminopeptidase N by new beta-amino thiols","volume":"37","author":"Chauvel","year":"1994","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.cjca.2022.01.019_bib10","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1021\/jm00091a016","article-title":"Mixed inhibitor-prodrug\u201d as a new approach toward systemically active inhibitors of enkephalin-degrading enzymes","volume":"35","author":"Fourni\u00e9-Zaluski","year":"1992","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.cjca.2022.01.019_bib11","doi-asserted-by":"crossref","first-page":"13415","DOI":"10.1073\/pnas.96.23.13415","article-title":"Aminopeptidase A inhibitors as potential central antihypertensive agents","volume":"96","author":"Reaux","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cjca.2022.01.019_bib12","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/cvr\/cvs420","article-title":"Inhibition of brain angiotensin III attenuates sympathetic hyperactivity and cardiac dysfunction in rats post-myocardial infarction","volume":"97","author":"Huang","year":"2013","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cjca.2022.01.019_bib13","doi-asserted-by":"crossref","first-page":"7775","DOI":"10.1073\/pnas.0402312101","article-title":"Brain renin-angiotensin system blockade by systemically active aminopeptidase A inhibitors: a potential treatment of salt-dependent hypertension","volume":"101","author":"Fournie-Zaluski","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cjca.2022.01.019_bib14","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1161\/HYPERTENSIONAHA.107.098772","article-title":"Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension","volume":"51","author":"Bodineau","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2022.01.019_bib15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/HYPERTENSIONAHA.112.190942","article-title":"Central antihypertensive effects of orally active aminopeptidase A inhibitors in spontaneously hypertensive rats","volume":"60","author":"Marc","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2022.01.019_bib16","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/HJH.0000000000001563","article-title":"Central antihypertensive effects of chronic treatment with RB150: an orally active aminopeptidase A inhibitor in deoxycorticosterone acetate-salt rats","volume":"36","author":"Marc","year":"2018","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.cjca.2022.01.019_bib17","first-page":"721","article-title":"Targeting brain aminopeptidase a: a new strategy for the treatment of hypertension and heart failure","volume":"36","author":"Marc","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2022.01.019_bib18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.yjmcc.2018.12.008","article-title":"Brain renin-angiotensin system blockade with orally active aminopeptidase A inhibitor prevents cardiac dysfunction after myocardial infarction in mice","volume":"127","author":"Boitard","year":"2019","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1016\/j.cjca.2022.01.019_bib19","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/FJC.0000000000000638","article-title":"Specific Inhibition of brain angiotensin iii formation as a new strategy for prevention of heart failure after myocardial infarction","volume":"73","author":"Leenen","year":"2019","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.cjca.2022.01.019_bib20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1042\/CS20130396","article-title":"A\u00a0new strategy for treating hypertension by blocking the activity of the brain renin-angiotensin system with aminopeptidase A inhibitors","volume":"127","author":"Gao","year":"2014","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.cjca.2022.01.019_bib21","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1399-3011.2004.00211.x","article-title":"Synthesis and in\u00a0vitro activities of new non-peptidic APA inhibitors","volume":"65","author":"Inguimbert","year":"2005","journal-title":"J\u00a0Pept Res"},{"key":"10.1016\/j.cjca.2022.01.019_bib22","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1161\/HYPERTENSIONAHA.118.12499","article-title":"NI956\/QGC006, a potent orally active, brain-penetrating aminopeptidase a inhibitor for treating hypertension","volume":"73","author":"Keck","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2022.01.019_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184237","article-title":"Involvement of arginine 878 together with Ca2+ in mouse aminopeptidase A substrate specificity for N-terminal acidic amino-acid residues","volume":"12","author":"Couvineau","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.cjca.2022.01.019_bib24","first-page":"83","article-title":"Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure","volume":"10","author":"Xu","year":"2004","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.cjca.2022.01.019_bib25","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1021\/bi9925726","article-title":"Histidine 450 plays a critical role in catalysis and, with Ca2+, contributes to the substrate specificity of aminopeptidase A","volume":"39","author":"Iturrioz","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.cjca.2022.01.019_bib26","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/nprot.2006.306","article-title":"A\u00a0continuous fluorescence resonance energy transfer angiotensin I-converting enzyme assay","volume":"1","author":"Carmona","year":"2006","journal-title":"Nat Protoc"},{"key":"10.1016\/j.cjca.2022.01.019_bib27","doi-asserted-by":"crossref","first-page":"R1293","DOI":"10.1152\/ajpregu.00339.2011","article-title":"Species-specific inhibitor sensitivity of angiotensin-converting enzyme 2 (ACE2) and its implication for ACE2 activity assays","volume":"301","author":"Pedersen","year":"2011","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.cjca.2022.01.019_bib28","doi-asserted-by":"crossref","first-page":"H423","DOI":"10.1152\/ajpheart.00685.2001","article-title":"The renin-angiotensin-aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failure","volume":"283","author":"Zhang","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.cjca.2022.01.019_bib29","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.yjmcc.2005.05.002","article-title":"Prevention of cardiac remodeling after myocardial infarction in transgenic rats deficient in brain angiotensinogen","volume":"39","author":"Lal","year":"2005","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1016\/j.cjca.2022.01.019_bib30","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1161\/01.RES.0000120864.21172.5A","article-title":"Prevention of sympathetic and cardiac dysfunction after myocardial infarction in transgenic rats deficient in brain angiotensinogen","volume":"94","author":"Wang","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2022.01.019_bib31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/10717540600559510","article-title":"Targeting the cerebrovascular large neutral amino acid transporter (LAT1) isoform using a novel disulfide-based brain drug delivery system","volume":"14","author":"Killian","year":"2007","journal-title":"Drug Deliv"},{"key":"10.1016\/j.cjca.2022.01.019_bib32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1161\/CIRCRESAHA.116.303577","article-title":"The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis","volume":"119","author":"Prabhu","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2022.01.019_bib33","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1161\/CIRCULATIONAHA.104.528695","article-title":"Angiotensin-converting enzyme inhibitors: a new mechanism of action","volume":"112","author":"Peng","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2022.01.019_bib34","doi-asserted-by":"crossref","first-page":"e882","DOI":"10.1097\/CCM.0000000000001646","article-title":"Acute bradykinin receptor blockade during hemorrhagic shock in mice prevents the worsening hypotensive effect of angiotensin-converting enzyme inhibitor","volume":"44","author":"Charbonneau","year":"2016","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cjca.2022.01.019_bib35","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1161\/hh1001.090759","article-title":"Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B(2) kinin receptor gene knockout mice","volume":"88","author":"Yang","year":"2001","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2022.01.019_bib36","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/HYPERTENSIONAHA.119.12675","article-title":"Evolution of a new class of antihypertensive drugs: targeting the brain renin-angiotensin system","volume":"75","author":"Llorens-Cortes","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2022.01.019_bib37","unstructured":"Gupta R, Alcantara R, Popli T, et\u00a0al. Firibastat: a novel brain aminopeptidase inhibitor, a new era of antihypertensive therapy. Curr Probl Cardiol. Online ahead of print. https:\/\/doi.org\/10.1016\/j.cpcardiol.2021:100859."},{"key":"10.1016\/j.cjca.2022.01.019_bib38","first-page":"775","article-title":"Brain ACE2 activation following brain aminopeptidase A blockade by firibastat in salt-dependent hypertension","volume":"135","author":"Hmazzou","year":"2021","journal-title":"Clin Sci Lond Engl 1979"},{"key":"10.1016\/j.cjca.2022.01.019_bib39","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/hr.2011.110","article-title":"Angiotensin-converting enzyme inhibition, but not AT(1) receptor blockade, in the solitary tract nucleus improves baroreflex sensitivity in anesthetized transgenic hypertensive (mRen2)27 rats","volume":"34","author":"Isa","year":"2011","journal-title":"Hypertens Res"},{"key":"10.1016\/j.cjca.2022.01.019_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048966","article-title":"Angiotensin-(1-7) in paraventricular nucleus modulates sympathetic activity and cardiac sympathetic afferent reflex in renovascular hypertensive rats","volume":"7","author":"Han","year":"2012","journal-title":"PloS One"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X22000691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X22000691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:49:25Z","timestamp":1760107765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X22000691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0828282X22000691"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2022.01.019","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"QGC606: A Best-in-Class Orally Active Centrally Acting Aminopeptidase A Inhibitor Prodrug for Treating Heart Failure Following Myocardial Infarction","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2022.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}